The search for new molecules that inhibit the NRF2 pathway to improve anticancer therapies have great therapeutic potential as supplementing traditional cancer therapies, although their use is not yet in clinical practice given their variable mechanisms of action and outcomes [46]. Here, NFE2L2 is linked to cancer.